[1] Jayarajan J, Radomski S. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol [Internet]. 2014 [acceso 12 de mayo de 2023];6. Disponible en: https://www.tandfonline.com/doi/full/10.2147/RRU.S40034
[2] Jayarajan J, Radomski S. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol [Internet]. 2014 [acceso 12 de mayo de 2023];6. Disponible en: https://www.tandfonline.com/doi/full/10.2147/RRU.S40034
[3] Eapen R, Radomski S. Gender differences in overactive bladder. Can J Urol. 2018; 23(supl 1):2-9. https://www.canjurol.com/html/free-articles/V23I1S1F-06_DrRadomski.pdf
[4] Patiño G, Sánchez C, Iregui J, Fernández J. Guía vejiga hiperactiva no neurogénica en adultos. Guía de la Sociedad Colombiana de Urología. Urol Colomb. 2016;25(1):62.e1-62.e15. https://www.elsevier.es/es-revista-urologia-colombiana-398-articulo-guia-vejiga-hiperactiva-no-neurogenica-S0120789X16000253
[5] Hamid R, Lorenzo-Gomez M-F, Schulte-Baukloh H, Boroujerdi A, Patel A, Farrelly E. OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice. Int Urogynecol J. 2021;32(1):65-74
[6] Información para prescribir actualmente aprobada para el producto Botox® https://www.abbvie.com.co/content/dam/abbvie-dotcom/co/Products/Botox100u/INSColombia.pdf
CO-BUO-240020